

**GOVERNMENT OF PAKISTAN**  
**THE PATENT OFFICE**  
2nd Floor, Kandawala Building,  
M.A. Jinnah Road,  
Karachi

No.2/2/2003-F.Sec.

Dated: **14-12-2006**

To,

The Manager,  
Printing Corporation of Pakistan Press,  
University Road,  
Karachi

Subject: **WEEKLY NOTIFICATION OF PATENT OFFICE FOR THE  
WEEK-ENDING 26-8-2006 TO BE PUBLISHED ON 14-12-2006  
IN THE GAZETTE OF PAKISTAN PART-V.**

A manuscript copy of the weekly notification regarding application filed application accepted and scaling fee due etc., is forwarded herewith to be published in the next issue of the Gazette of Pakistan Part-V without fail.

(Mrs. Yasmeen Abbasi)  
Controller of Patents & Designs  
Ph: 9215488

ENCL:

## NEW APPLICATIONS FOR THE PATENTS

The dates shown in the crescent brackets are the dates claimed under section 86 of the Patents Ordinance 2000.

1014/2006	<b><u>21-8-2006</u></b> Merck & Co., USA (Priority 22-11-02 USA) <b>Divisional</b>	“A pharmaceutically acceptable salt of N-[4-aryl and heteroaryl)-2-(5-aryl and heteroaryl)-1-methyl propyl]2-2(aryl and heteroaryl oxy)2-methyl propanamide derivatives useful as CB1 antagonists/inverse agonists”
1015/2006	Akzo Nobel N.V, The Netherlands (Priority 23-8-05 Europe)	“ Indole derivatives”
1016/2006	Sanofi-Aventis Deutschland GmbH, Germany (Priority 02-12-003 Germany) <b>Divisional</b>	“ (S)-n- {2-[3-oxo-2-(2,2,2-trifluoroethyl)-6-(trifluoroethyl-2,3-dihydro-1H-isoindol-1-yl]acetyl} guanidine hydrogenfumarate hydrate”
1017/2006	Novartis AG., Switzerland (Priority 22-8-05 GB)	“ Solid pharmaceutical compositions comprising 1-(4- chloroanilino) -4-(4-pyridylmethyl) phthalazine and a pH modifier”
1018/2006	<b><u>22-8-2006</u></b> Muhammad Rafique Shakir, Sawat, Pakistan	“A wide spectrum ointment composition and a process for preparation thereof”
1019/2006	Tianjin Tasly Pharmaceutical Co., Ltd, China (Priority 24-8-05 China)	“ A composition of traditional Chinese medicine for treating headache, the preparations and the process making the same”
1020/2006	1.Emisphere Technologies, Inc, USA 2. F. Hoffmann-La Roche AG, Switzerland (Priority 24-8-05 USA)	“ Improved Ibandronate Formulations”
1021/2006	Laura Micol Fisher, Italy,	“ Rotatable building structure”

1022/2006	Bayer HealthCare AG, Germany (Priority 29-5-05 Europe)	“PDE inhibitors and combinations thereof for the treatment of urological disorders”
1023/2006	Pioneer HI-Bred International, Inc., USA (Priority 24-8-05 USA)	“ Compositions providing tolerance to multiple herbicides and methods of use thereof”
1024/2006	Eisai R&D Management Co, Ltd. Japan (Priority 24-8-05 USA)	“ Novel pyridine derivatives and pyrimidine derivatives (3)”
1025/2006	Boehringer Ingelheim International GmbH, Germany (Priority 24-8-05 Germany)	“ Atomiser”
1026/2006	Wyeth, USA (Priority 24-8-05 USA)	“ Process for preparing $\beta$ -lactamase inhibitors”
1027/2006	1.Cytokinetics, Inc., 2. SmithKline Beecham Corporation, USA (Priority 17-4-02 USA) <b>Divisional</b>	“ A pharmaceutical acceptable salt of a benzopyran-4-one/chromen 4-one as inhibitor of mitotic kinesins”
1028/2006	Novartis AG., Switzerland (Priority 25-8-05 USA)	“ Organic compounds”
1029/2006	<b><u>23-8-2006</u></b> Starpak Martial Arts (Pvt) Ltd. Sialkot, Pakistan.	“ A sports Glove”
1030/2006	Wyeth, USA (Priority 15-10-02 USA) <b>Divisional</b>	“ A composition comprising a pharmaceutically acceptable salt of milnacipran for preventing and treating vasomotor symptoms”
1031/2006	SmithKline Beecham Biologicals s.a. Belgium (Priority 07-9-99 UK) <b>Divisional</b>	“ A vaccine comprising a human papillomavirus, method of its preparation and use in therapy”

1032/2006	Wyeth, USA (Priority 24-8-05 USA)	“ Bazedoxifene acetate formulations”
1033/2006	1. Idenix Pharmaceuticals, Inc, USA, 2. Centre National De La Recherche Scientifique (CNRS), France, (Priority 23-8-05 USA)	“ Seven- membered ring nucleosids”
1034/2006	Nokia Corporation, Finland, (Priority 23-8-05 USA)	“ Radio link control unacknowledged mode header optimization”
1035/2006	MERZ Pharma GmbH & Co, KGAA, Germany, (Priority 24-8-05 PCT)	“ Tetrahydroquinolines and their use as modulators of metabotropic glutamate receptors”
1036/2006	JUN Byoung Pyo, Republic of Korea, (Priority 29-6-06 Korea)	“ Combustion promoting device for internal combustion engine”
1037/2006	KuDOS Pharmaceuticals Ltd, UK, (Priority 31-8-05 USA)	“ ATM Inhibitor”
1038/2006	Zimmer AG, Germany, (Priority 26-8-05 DE)	“ Method and device to reduce the acetaldehyde content of polyester granulate”
1039/2006	Laboratories Del Dr. Esteve, S.A, Spain, (Priority 14-11-2001 Spain) <b>Divisional</b>	“ A physiologically acceptable salt of a sulphonamide- derived compound and a pharamaceutical composition comprising thereof”
1040/2006	Laboratorios Del Dr. Esteve, S.A, Spain, (Priority 14-11-2001 Spain) <b>Divisional</b>	“ A physiologically acceptable salt of a sulphonamide- derived compound and a pharamaceutical composition comprising thereof ”
1041/2006	Laboratorios Del Dr. Esteve, S.A, Spain, (Priority 14-11-2001 Spain) <b>Divisional</b>	“ A physiologically acceptable salt of a sulphonamide- derived compound and a pharamaceutical composition comprising thereof ”
1042/2006	E.I. Du Pont Nemours and	“ Novel anthranilamides for controlling

	Company, USA (Priority 25-8-05 USA)	invertebrate”
	<b><u>24-8-2006</u></b>	
1043/2006	Solvay (Societe Anonyme), Belgium (Priority 12-9-05 Europe)	“ Aqueous solution suitable for the chemical sterilization of packaging materials, process for its preparation and its use”
1044/2006	SmithKline Beecham Corporation, USA (Priority 26-8-05 USA)	“ Pyrimidinyl-pyrazole inhibitors of aurora kinases”
1045/2006	DyStar Textilfarben GmbH & Co. Deutschland KG, Germany (Priority 26-8-05 Germany)	“ Mediator systems for electrochemical reduction of organic compounds in aqueous solution”
1046/2006	Laboratorios Del Dr. Esteve, S.A, Spain, (Priority 09-4-2002 Spain) <b>Divisional</b>	“ A pharmaceutically acceptable salt of a benzoxazinone- derived compound its preparation and pharmaceutical composition comprising thereof”
1047/2006	DyStar Textilfarben GmbH & Co. Deutschland KG, Germany (Priority 26-8-05 Germany)	“ Dye preparations of indigoid dyes, of vat and sulfar dyes comprising inorganic and/ or organic electrochemically active mediator systems and use thereof”
1048/2006	AstraZeneca AB, Sweden (Priority 15-3-04 USA) <b>Divisional</b>	“A pharmaceutically acceptable salt of substituted heterocycle and the use thereof”
1049/2006	AstraZeneca AB, Sweden (Priority 16-9-03 GB) <b>Divisional</b>	“A pharmaceutically acceptable salt of a quinozoline derivative”
1050/2006	Janssen Pharmaceutica N.V., Belgium (Priority 13-3-02 USA) <b>Divisional</b>	“A pharmaceutically acceptable salt of sulfonyl-derivative as novel inhibitor of histone deacetylase”
1051/2006	Merck & Co, Inc., USA <b>Divisional</b>	“A pharmaceutically acceptable salt of acylated piperazine derivative as melanocortin-4 receptor agonist”

1052/2006	Wyeth, USA (Priority 16-12-2002 USA) <b>Divisional</b>	“A pharmaceutically acceptable salt of (1-[3-chloro-4-(5H-pyrrolo[2,1-C][1,4]b enzodiazepine-10(1H0-ylcarbonyl) phenyl]-1H-pyrazole derivatives useful as vasopressin agonists”
1053/2006	1. Idenix Pharmaceuticals, Inc., USA 2. The Chancellors, Masters England 3. Novartis AG., Switzerland (Priority 26-8-05 USA)	“ Process for preparing saccharinic acids and lactones”
1054/2006	<u><b>25-8-2006</b></u> AstraZeneca AB, Sweden (Priority 27-6-03 Sweden) Divisional	“ N-hydroxyformamide derivative useful in the inhibition of metalloproteinases”
1055/2006	AstraZeneca AB, Sweden (Priority 27-6-03 Sweden) <b>Divisional</b>	“ N-hydroxyformamide derivative useful in the inhibition of metalloprotenases”
1056/2006	AstraZeneca AB, Sweden (Priority 27-6-03 Sweden) <b>Divisional</b>	“ N-hydroxyformamide derivative useful in the inhibition of metalloproteinases”
1057/2006	Bristol-Myers Squibb company, USA (Priority 17-11-2000 USA) <b>Divisional</b>	“ Pyrrolotriazine compound useful as kinase inhibitor”
1058/2006	AstraZeneca AB, Sweden (Priority 26-6-2001 Sweden) <b>Divisional</b>	“ Salt of amino nicotinate derivative as glucokinase (GLK) modulator”
1059/2006	1. Bristol-Myers Squibb company, and 2. Icagen Inc., USA (Priority 01-2-2002 USA) <b>Divisional</b>	“ A pharmaceutically acceptable salt of novel cycloalkyl compounds useful as inhibitors of potassium channel function”
1060/2006	1. Bristol-Myers Squibb	“ Novel diastereomer cycloalkyl

	company, and 2. Icagen Inc., USA (Priority 01-2-2002 USA) <b>Divisional</b>	compound useful as inhibitor of potassium channel function”
1061/2006	1. Bristol-Myers Squibb company, and 2. Icagen Inc., USA (Priority 01-2-2002 USA) <b>Divisional</b>	“ Novel enantiomer cycloalkyl compound useful as inhibitor of potassium channel function”
1062/2006	Siemens Ltd., Brazil (Priority 25-8-05 USA)	“ dynamic system for controlling economic profitability of power transformers and method for the optimization of the economic profitability of power transformers”
1063/2006	Sanofi-Aventis Deutschland GmbH, Germany (Priority 03-6-2002 France) <b>Divisional</b>	““ A pharmaceutically acceptable salt of an isoindolone derivative, preparation process and a pharmaceutical composition thereof”
	<b><u>26-8-2006</u></b>	
1064/2006	AstraZeneca AB, Sweden (Priority 06-9-2005 Sweden)	“ Novel Compound ”
1065/2006	Bayer CropScience AG, Germany (Priority 15-9-05 Germany)	“ Dioxazine-and oxdiazine-substituted arylamides”
1066/2006	Novozymes A/S, Denmark (Priority 26-8-05 Denmark)	“ Polypeptides aving antimicrobial activity and polynucleotides encoding same”
1067/2006	Wyeth, USA (Priority 14-10-2003 USA) <b>Divisional</b>	“ Pharmaceutically acceptable salts of substituted phenyl-piperidinyl- alkylcyclohexanol derivatives”
1068/2006	Sanofi-Aventis U.S. LLC USA (Priority 29-8-05 USA)	“ Novel crystalline form”
1069/2006	SmithKline Beecham P.l.c.	“ A combination of a thiazolidinedione,

	Uk (Priority 18-7-97 UK) <b>Divisional</b>	an insulin secretagogue, and a biguanide for the treatment of diabetes mellitus”
1070/2006	Sanofi-Aventis U.S. LLC USA (Priority 29-8-05 USA)	“ Amorphous solid dispersions”
1071/2006	Deere and Company, USA (Priority 29-8-05 USA)	“ Cotton harv-picker-conditioner at row unit input”
1072/2006	Albemarle corporation, USA (Priority 19-9-05 USA)	“ Highly concentrated pourable aqueous solutions of potassium ibuprofen, their preparation and their uses”

#### APPLICATION ACCEPTED

Notice is hereby given that the person interested in opposing the grant of Patents to any of the applications referred to below at any time within four months from the date of this Gazette may give notice at the Patent Office on the prescribed Form P-7 of the Patents Rules 18(1) of 2003.

The six figures number shown in the right hand side are those given to applications on acceptance of the complete specification under which the specification will be printed and subsequent proceeding taken.

The figures shown within square brackets after the title of inventions indicated their classification index at acceptance.

Typed copies of the specification which are to open to public inspection can be supplied by the Patent Office on payment of the prescribed charges which may be ascertained on application to the office.

935/2004	Bristol-Myers Squibb Pharma Company, USA	“A process for the preparation of a pyrazolo[1, 5-A]-1, 3, 5-triazine”  (Class: INT.CL: C07D 471/02)
----------	--	--

139218

Comprising to: pyrazolo (1, 5-a)-1, 3, 5-triazine compound, to its process of preparation, useful for treating corticotropin releasing factor (CRF) related disorders such as anxiety and depression.

941/2004	Invista Technologies S.a.r.l., USA	“A composite yarn comprising one or more elastomeric fibers and hard yarns and a method for making same”  (Class: INT.CL.7: D02G, 1/20)	139219
946/2004	Wyeth, USA	This application relates to composite yarns, comprising one or more elastomeric fibers and hard yarns, are formed by adhering the elastomeric fibers and hard yarn together using a size material; which may be used in weaving and knitting to make stretch fabric with desired garment characteristics. “Process for carbon-carbon cross coupling catalyzed by transition metals on solid supports”  (Class: INT.CL.7: B01J, 23/00)	139220
		A method of coupling carbon-containing compound comprising reacting (i) a first carbon containing compound, with (ii) a second carbon-containing compound, in the presence of (iii) palladium or nickel metal on a solid support comprising an alkaline earth metal salt, and (iv) a solvent comprising an alcohol.	

**SEALING FEES DUE**

Notice is hereby given that the Patent may now be sealed on the application referred to below if it is desired that Patent should be sealed a request on the prescribed Form-10 accompanied by the fee of Rs.2250/- should be sent to the Controller of Patents and Designs, The Patent Office, Karachi.

139032	National Institute for biotechnology, Faisalabad, Pakistan	567/2004
--------	---	----------

139033	SmithKline Beecham Corporation, USA	574/2004
139034	Wyeth USA	580/2004
139035	Honda Motor Co., Ltd. Japan	584/2004
139036	Wyeth Holdings Corporation. USA	585/2004
139037	Norsk Hydro ASA, Norway	861/2004
139038	Mayo foundation for Medical Education and Research, USA	870/2004
139039	Au Vironic Limited, Pakistan	961/2004

(Mrs. Yasmeen Abbasi)  
Controller of Patents & Designs  
Tel: 9215488